FIG 6.

TNP preferentially activate PLD1 in HIV-infected cells. Mock- and HIV-infected macrophages and CD4⁺ T cells were exposed to 400 μg ml⁻¹ PLGA nanoparticles, 400 μg ml⁻¹ RBC-NP, or TNP for 4 h, washed three times with PBS, and then incubated for a further 24 h before cells were harvested and lysed. n = 4. (A) Lysates were evaluated for PLD activity. (B) Lysates were evaluated for phosphatidic acid (PA) content. (C and D) HIV-infected macrophages (C) and CD4⁺ T cells (D) were pretreated for 1 h with the PLD1 inhibitor VU0359595 or VU0155069 (both at 1 μM) before exposure to 400 μg ml⁻¹ TNP. Lysates were evaluated for PLD activity (left) and for PA content (right).